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significant boost this past year with the
approval of the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) mRNA
vaccines developed by Biotech/Pfizer and
Moderna. In addition to such mRNA-based
vaccines, self-amplifying RNA (sa-RNA)
can also be used for vaccination.1 In addition
to the transgene product, the sa-mRNA en-
codes an RNA-dependent RNA polymerase,
which permits self-replication of the tran-
script, thereby increasing the level and dura-
tion of protein expression and allowing
application of lower doses. This longer-last-
ing effect may even obviate the need for a
booster vaccine. The aim of any vaccine is
to induce potent immune responses. Para-
doxically, innate immune responses elicited
by sa-mRNA vaccines may lower their effec-
tiveness. In this issue of Molecular Therapy,
Zhong et al.2 show that inhibition of the
type 1 interferon (IFN I) response to sa-
RNA using corticosteroids and other inhibi-
tors substantially increased production of the
sa-mRNA-encoded protein antigen but, un-
fortunately, was detrimental to the vaccine
effect. However, modification of the purifica-
tion method to eliminate double-stranded
RNA (dsRNA) byproducts during sa-
mRNA production reduced innate immunity
and improved the efficacy of a Zika virus vac-
cine, resulting in higher antibody titers and
T cell responses against Zika target antigen.
To manufacture the sa-RNA vaccine, line-
arized plasmid DNA is used as a template
for transcription by T7 RNA polymerase.
dsRNA is generated as a byproduct during
this process. Following delivery of the vac-
cine, the dsRNA induces IFN I production
through activation of innate immune re-
ceptors that can reside on cell surfaces or
in the cytoplasm, such as toll-like receptorMolecula3 or retinoic acid-inducible gene I (RIG-I).
Induction of antigen-specific immune re-
sponses—the goal of vaccination—requires
activation signals provided by such innate
immune sensors. The latter recognize
pathogen-associated molecular patterns
(PAMPs), such as those generated during
infection by dsRNA viruses, and help alert
the immune system to an infection. One
can mimic these effects by the inclusion
of adjuvant molecules that are similar to
naturally occurring PAMPs in vaccine for-
mulations. Innate immune signals induce
cytokine production and prompt dendritic
cells and other antigen-presenting cells to
provide co-stimulation to T cells, all of
which aid in the generation of an adaptive
immune response. One could therefore
speculate that contamination of the sa-
mRNA vaccine with innate immune acti-
vating dsRNA might enhance the vaccine.
However, this view is overly simplistic.
The type, strength, and timing of innate sig-
nals all critically influence the vaccination
outcome. In the context of sa-mRNAvaccines,
dsRNA molecules, in particular, induce IFN I
responses. IFN I has been described as a crit-
ical regulator of mRNA-based vaccines and
also plays a crucial role in antiviral T cell re-
sponses. For instance, sensing of IFN I by con-
ventional dendritic cells is a major factor in
their ability to activate CD8+ T cell responses
in adeno-associated viral gene transfer, result-
ing in unwanted immune responses in gene
therapy.3 However, this does not necessarily
mean that dsRNA-induced IFN I will have
the desired immune stimulatory effect on
RNA-based vaccines. As is the case with other
cytokines, IFNa and IFNb produce pleio-
tropic effects. IFN I contributes to activation
of dendritic cells, enhances co-stimulation,
and also directly stimulates T cells. However,r Therapy Vol. 29 No 4 April 2021 ª 2021 The AmIFN I cytokines can also induce an antiviral
state in cells to limit gene expression and
thereby suppress viral replication. For a vac-
cine, the consequencemay be reduced expres-
sion of the vaccine antigen, which ironically
lowers vaccine efficacy. To address this issue,
Zhong et al.2 topically applied corticosteroids
at the site of vaccine administration in mice
prior to intradermal electroporation. The ste-
roids suppressed IFN I production, and the
approach was ultimately successful in raising
expression, as measured by a luciferase re-
porter coexpressed from the sa-mRNA (see
Figure 1). The effect could be further
enhanced by inclusion of inhibitors of specific
innate immune signaling pathways. At the
same time, however, the immune-suppressive
effect of the steroids completely prevented
vaccination against Zika virus, possibly by
suppressing the required immune stimulatory
effects of IFN I and/or suppression of other
components of the immune response.
In an alternative approach to the problem,
the authors aimed to find ways to eliminate
dsRNA molecules from their vaccine prep-
arations rather than suppressing their ef-
fects. This was accomplished by switching
from silica- to cellulose-based purification
of the produced RNA. An optimized puri-
fication technique eliminated most of the
dsRNA, resulting in multiple beneficial ef-
fects on the vaccine. Not only was innate
immunity reduced, but vaccine efficacy
against Zika virus was much improved by
multiple measures, including increased
seroconversion, antibody titers, and the
magnitude of CD4+ and CD8+ T cell re-
sponses. These observations should serve
as a guide for general improvements in
development of sa-RNA vaccines. Since
electroporation is not easily scalable for de-
livery, it would be interesting to determineerican Society of Gene and Cell Therapy. 1
Figure 1. Inhibition of the type 1 interferon (IFN I) response to sa-RNA using corticosteroids and other
inhibitors increases production of the sa-mRNA-encoded transgene but is detrimental to the vaccine
effect
The application of corticosteroids at the site of vaccine administration in mice prior to intradermal electroporation
suppresses IFN I production and vaccine efficacy (top right panel) but increases expression of a luciferase reporter
coexpressed from the sa-mRNA (bottom right panel). Modification of the saRNA purification protocol to eliminate
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(LNPs) is similarly affected. Certain lipo-
somes, themselves, can activate dendritic2 Molecular Therapy Vol. 29 No 4 April 2021cells, so it should be possible to deliver
sa-mRNA vaccines that are dsRNA-free
without the need for additional adjuvants.4However, one needs to keep in mind that
the magnitude of the resulting T cell
response is also dependent on the route
of mRNA-lipoplex administration and
that regulation of the immune response
by IFN I does not entirely take place at
the dendritic cell level.5REFERENCES
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